The VE-BASKET trial [109] enrolled 24 patients with BRAF V600-mutant gliomas, including 11 recurrent high-grade gliomas (six GBM and five anaplastic astrocytoma); for these patients, the median PFS was 5.3 months (95% CI, 1.8–12.9), the median OS was 11.9 months (95% CI, 8.3–40.1) and the ORR was 9.1%. This evidence concerns the gene BRAF and glioma.